

Lutetium-177 vipivotide tetraxetan for treating PSMA- positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

Information for the public

Published: 15 November 2023

www.nice.org.uk

Lutetium-177 vipivotide tetraxetan (Pluvicto) is not normally available on the NHS for treating prostate-specific membrane antigen (PSMA)-positive hormone-relapsed metastatic prostate cancer in adults:

- after taxane-based chemotherapy and an anti-androgen or
- when taxanes are 'medically unsuitable'.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpage on prostate cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Tackle Prostate Cancer](#), 0800 035 5302
- [Prostate Cancer UK](#), 0800 074 8383
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5526-8